Pituitary neuroendocrine tumors: from old treatments to innovations, from efficacy to tolerance, from benignity to carcinomas, where do we stand now?

Frederic Castinetti; Gerald Raverot

doi:10.1016/j.beem.2022.101717

Journal Articles Best Practice and Research: Clinical Endocrinology and Metabolism Year : 2022

Pituitary neuroendocrine tumors: from old treatments to innovations, from efficacy to tolerance, from benignity to carcinomas, where do we stand now?

(1, 2, 3) ,

1
2
3

Frederic Castinetti

Function : Author
PersonId : 16755
IdHAL : frederic-castinetti
ORCID : 0000-0002-1808-8800
IdRef : 113296061

Marseille medical genetics - Centre de génétique médicale de Marseille

Institut Marseille Maladies Rares

Service d'endocrinologie, diabète, maladies métaboliques [Hôpital de la Conception - APHM]

Gerald Raverot

Function : Author

Domains

Life Sciences [q-bio] Human health and pathology Endocrinology and metabolism Life Sciences [q-bio] Human health and pathology

Valérie Gall : Connect in order to contact the contributor

https://hal-amu.archives-ouvertes.fr/hal-04034400

Submitted on : Friday, March 17, 2023-2:22:40 PM

Last modification on : Saturday, March 18, 2023-3:38:27 AM

Dates and versions

hal-04034400 , version 1 (17-03-2023)

Identifiers

HAL Id : hal-04034400 , version 1
DOI : 10.1016/j.beem.2022.101717

Cite

Frederic Castinetti, Gerald Raverot. Pituitary neuroendocrine tumors: from old treatments to innovations, from efficacy to tolerance, from benignity to carcinomas, where do we stand now?. Best Practice and Research: Clinical Endocrinology and Metabolism, 2022, 36 (6), pp.101717. ⟨10.1016/j.beem.2022.101717⟩. ⟨hal-04034400⟩

Export

BibTeX TEI Dublin Core DC Terms EndNote Datacite

Collections

UNIV-AMU MMG

0 View

0 Download

Pituitary neuroendocrine tumors: from old treatments to innovations, from efficacy to tolerance, from benignity to carcinomas, where do we stand now?

Domains

Dates and versions

Identifiers

Cite

Export

Collections

Altmetric

Share